Who holds the patent for Cefoperazone/Sulbactam?

Introduction to Cefoperazone/Sulbactam

Cefoperazone/sulbactam is a well-established antibiotic combination used for the treatment of various bacterial infections, particularly in hospital settings. The combination pairs cefoperazone, a third-generation cephalosporin, with sulbactam, a β-lactamase inhibitor, in order to enhance antibacterial activity and overcome bacterial resistance mechanisms. This introduction lays a foundation by reviewing the individual components, their role in combination therapies, and the broad clinical relevance of the product.

Overview of Cefoperazone

Cefoperazone is a third-generation cephalosporin that acts primarily by disrupting bacterial cell wall synthesis. Its spectrum spans both Gram-positive and Gram-negative bacteria, and it has seen widespread usage since its initial approval in several territories starting in the early 1980s. The drug’s pharmacokinetic profile, characterized by a relatively long elimination half-life, allows for convenient twice-daily dosing regimens in certain clinical scenarios. Historically, cefoperazone has been embraced in the treatment of severe infections such as nosocomial pneumonia, intra-abdominal infections, and other systemic infections, leveraging its broad antibacterial activity.

Overview of Sulbactam

Sulbactam is not only a β-lactamase inhibitor but also possesses intrinsic antibacterial activity against specific pathogens, particularly Acinetobacter spp. By binding to β-lactamases, sulbactam protects cefoperazone from enzymatic degradation, thereby extending the spectrum of activity against β-lactamase-producing bacteria. Its inclusion in the combination mitigates one of the key resistance mechanisms that would otherwise limit the clinical utility of cefoperazone, thus rendering the drug combination more effective for a plethora of bacterial infections.

Combination Use in Medicine

The rationale for combining cefoperazone with sulbactam lies in their complementary mechanisms of action. In clinical practice, this combination is widely used to treat infections that are often challenging due to resistance issues. It has been developed into various formulations – ranging from powder forms to injectable solutions – that are tailored to clinical needs. The combination not only improves the in vitro antibacterial efficacy but has been demonstrated to be clinically effective and safe in multiple studies across diverse patient populations. Consequently, cefoperazone/sulbactam is considered a first-line option in several treatment guidelines, particularly in areas where resistant Gram-negative pathogens are prevalent.

Patent Information

Patent protection is a critical aspect of pharmaceutical innovation. It delineates the rights of the holders over discoveries and methods associated with drug development and manufacturing. For a widely used combination product like cefoperazone/sulbactam, various patents exist that cover distinct aspects – including manufacturing processes, formulation methods, and even specific dosage forms. In this section, we delve into the nuances of drug patents, identify the current patent holders, and discuss the implications of patent expiries.

Understanding Drug Patents

Drug patents can cover a diverse range of inventions: the novel chemical entities themselves, formulations that provide enhanced stability or bioavailability, manufacturing methods, and even new therapeutic uses. For combination drugs, patents may address the innovative way of combining two agents to achieve a synergistic effect. In the case of cefoperazone/sulbactam, patents have been issued for specific formulation approaches and mixing methods that ensure the stability and uniform distribution of the active ingredients. A robust patent portfolio not only protects these technological advancements but also helps in carving out market exclusivity, fostering innovation while ensuring that competitors do not replicate the benefits without authorization.

Current Patent Holders

The landscape of patent ownership for cefoperazone/sulbactam is multi-faceted. Specific patents addressing the formulation and manufacturing of this antibiotic combination have been assigned to distinct corporate entities from different regions. Two key examples from the available synapse-sourced references are as follows:

Powder Mixing Method Patent
One patent, identified as “A kind of powder mixing method of cefoperazone sodium and sulbactam sodium” (Patent No. CN103655578B), this patent describes a unique method whereby the raw powders for cefoperazone sodium and sulbactam sodium are mixed by intentionally deviating the mixing machine’s rotation axis, thereby ensuring uniform dispersion of the powders. The explicit innovation in the mixing technique plays a significant role in the consistent quality of the final drug product.

Pharmaceutical Composition Patent
Another pertinent patent is titled “Pharmaceutical composition of cefoperazone sodium and sulbactam sodium” (Patent No. WO2017117880A1), where the WO2017117880A1 consortium of companies: SICHUAN PHARMACEUTICAL.IN, SICHUAN XINGZHI ZHIHUI INTELLECTUAL PROPERTY OPERATION CO., LTD. This patent covers the pharmaceutical formulation aspect of the combination, which specifies the mass ratios of the active ingredients as well as defining critical quality attributes like the specific rotations of the compounds. Such detailed information ensures that production processes are standardized and the product meets rigorous clinical safety and efficacy requirements.

It is important to note that the patent portfolio for cefoperazone/sulbactam is not monolithic; multiple patents across different jurisdictions may address separate components—including formulations, process technologies, and package configurations—that together secure the intellectual property behind the product. The patents hold strategic value in maintaining market monopoly and protecting against generic competition during the exclusivity period.

Patent Expiry and Implications

While the patents discussed above secure a period of exclusivity, they are subject to expiration dates that vary depending on the filing and publication dates as well as any extensions that might be granted. For instance, patents like CN103655578B and WO2017117880A1 have specific expiration dates (which may be extended subject to regulatory data protection or patent term extensions) that determine how long the patent holders can exclusively manufacture and market the drug before generic entities may enter the market.

Patent expiration opens the opportunity for generic manufacturers to produce and market generic versions. However, the expiry of patent rights does not necessarily correlate with a decline in the overall clinical utility or market presence of the combination; rather, it often leads to increased competition, which might drive down prices and improve accessibility for patients.

Additionally, these expiration dates influence strategic decisions regarding lifecycle management from the patent holders’ perspectives. Companies will often explore additional patents covering novel formulations or extended indications (such as pediatric uses or new methods of administration) to prolong their market exclusivity periods even after the core patent expires. This strategic layering of patents is common in the pharmaceutical industry to balance the inherent costs of R&D and manufacturing with the competitive pressures of the market.

Legal and Market Implications

The legal landscape surrounding drug patents, particularly for combination antibiotics like cefoperazone/sulbactam, profoundly influences market dynamics and the competitive environment. In this section, we analyze how patents affect market competition and the common legal challenges that arise when patent protection is asserted.

Impact on Market Competition

Patent protection, by design, restricts market entry by competitors during the exclusivity period. For cefoperazone/sulbactam, the patents held by companies such as Tiansheng Pharmaceutical Group and the consortium represented by SICHUAN PHARMACEUTICAL.IN and its partners enable these entities to secure a dominant market share in their respective territories. This exclusivity allows the patent holders to recoup investments in research, development, and manufacturing process optimization.

From a market perspective, the authorized holders gain the ability to set pricing that reflects the cost of innovation while managing supply chains and ensuring high product quality. However, as patents eventually expire, the market typically witnesses a surge in generic competition. The subsequent entry of generic manufacturers often leads to reduced prices, thereby benefiting healthcare systems but potentially reducing the revenue streams of the original patent holders.

Moreover, the competition extends beyond simple market entry; legal disputes sometimes arise over the alleged infringement of patents, or challenges related to the validity of a patent itself. The legal landscape is dynamic, with patent owners frequently engaged in litigation to defend their intellectual property rights. Such actions are common in the pharmaceutical industry and reflect the high stakes associated with drug market exclusivity.

Legal Challenges and Disputes

Patent litigation in the pharmaceutical sector is intricate and often requires detailed technical and legal arguments. In the case of cefoperazone/sulbactam:

Defensive Measures: The patent holders must continually monitor the market and address any potential infringement that may arise from competitors attempting to produce similar products without authorization. Such litigation might involve complex questions of whether a competing product has infringed upon the specific claims of the patent as outlined in the formulation or mixing process patents.

Patent Validity and Enforcement: Legal challenges may also be directed at the validity of the patents themselves. Generic manufacturers or other competitors might challenge the novelty or inventive step of aspects of the patent, arguing that similar methods exist or that the innovation does not meet the required threshold for patentability. These disputes could potentially lead to modifications or severance of claims, thereby affecting the extent of patent protection.

Cross-Jurisdictional Variations: Patent disputes also vary by region since different patent offices and courts may interpret the scope and validity of the claims differently. For instance, while a patent issued in China may be upheld against a specific infringement claim, a similar claim in another jurisdiction might be subject to different standards. This multi-jurisdictional reality means that companies holding patents on cefoperazone/sulbactam need to engage in comprehensive legal strategies across regions.

Ultimately, such legal challenges shape the market dynamics and can influence the duration of exclusivity that the original patent holders can maintain. Stakeholders must navigate through these challenges while balancing innovation with competitive pressures.

Future Prospects

Looking ahead, the evolution of the cefoperazone/sulbactam product, along with its patent portfolio, is influenced by ongoing research, market dynamics, and regulatory changes. Here we discuss prospects on advancements in antibiotic combinations and the eventual potential for generic production once core patents expire.

New Developments in Antibiotic Combinations

Pharmaceutical research continues to push the boundaries on antibiotic combinations to address the evolving challenge of bacterial resistance. Novel adjuncts to existing combinations, improved formulations, and innovative methods of drug delivery are being actively explored. For cefoperazone/sulbactam, new studies are investigating alternative ratios, optimized dosing regimens via pharmacokinetic/pharmacodynamic (PK/PD) modeling, and expanded indications for use. For example, recent research has focused on exploring different ratios beyond the traditional 2:1 combination to maximize efficacy while minimizing dosage frequency and potential toxicity.

Such developments not only improve clinical outcomes but also serve as a basis for new patent applications. Should companies decide to develop a new formulation or combination therapy that improves patient outcomes relative to the legacy product, subsequent patents could provide additional layers of protection. This strategy is common among pharmaceutical companies to maintain market advantage even if the original patents expire.

Potential for Generic Drug Production

The expiration of foundational patents such as those held by Tiansheng Pharmaceutical Group and the consortium led by SICHUAN PHARMACEUTICAL.IN heralds the impending opportunity for generic drug production. As patents near or reach their expiry dates, generic manufacturers are poised to enter the market, offering cefoperazone/sulbactam at lower prices.

Generic entry is viewed positively from the patient care perspective because it increases the accessibility and affordability of essential medications. However, it also signifies a shift in market dynamics wherein the original companies must innovate further or leverage secondary patents to maintain market share. The interplay of market exclusivity, pricing regulations, and patent cliff effects is a well-documented phenomenon across the pharmaceutical industry and is highly relevant to cefoperazone/sulbactam.

Generic manufacturers are expected to invest in demonstrating bioequivalence and meeting stringent regulatory requirements before receiving market authorization. This process often involves complex clinical and analytical studies to ensure that the generic product matches the innovator in terms of safety, efficacy, and quality. Furthermore, the entry of generics prompts original patent holders to consider strategies such as lifecycle management, including reformulations or alternate delivery mechanisms, to sustain their competitive edge.

Conclusion

In summary, the patent protection for cefoperazone/sulbactam is held by multiple prominent entities that have developed and patented various aspects of the drug’s composition, manufacturing process, and formulation. The key patents include one held by Tiansheng Pharmaceutical Group for the powder mixing method and another held jointly by SICHUAN PHARMACEUTICAL.IN, SICHUAN XINGZHI ZHIHUI INTELLECTUAL PROPERTY OPERATION CO., LTD. for the pharmaceutical composition. These patents play crucial roles in maintaining market exclusivity and protecting the investments made in the antibiotic combination. However, the patent landscape is dynamic, influenced by legal challenges, expiration timelines, and subsequent innovation, all of which impact both market competition and clinical practice.

From a general perspective, drug patents serve as both a protective mechanism and an incentive for further research. Specifically, in the case of cefoperazone/sulbactam, the multiple patents covering the mixing methods and composition formulations ensure that significant investments are safeguarded while providing a framework for continuous improvement and clinical application. On a more specific level, identifying the current patent holders reveals the diversified nature of intellectual property rights in this domain. For instance, Tiansheng Pharmaceutical Group and the consortium of companies under SICHUAN PHARMACEUTICAL.IN are at the forefront of this innovation, as evidenced by their detailed patent filings. Finally, taking a broad view once again, these patents collectively influence market behavior, legal jurisprudence, and future developments in antibiotic therapy—highlighting the interconnectedness of intellectual property, regulatory strategies, and clinical benefits.

The implications of patent expiry are significant. As the patents eventually lapse, the market is likely to see an influx of generic products which could enhance patient access and drive down costs. In anticipation of this, original patent holders may already be laying the groundwork for next-generation products, thereby extending their exclusivity through incremental innovations. Moreover, the legal challenges associated with patent infringement claims and validity disputes will continue to shape the competitive landscape.

In explicit conclusion, the current patent holders for cefoperazone/sulbactam—as revealed from the structured synapse sources—are multifaceted. The powder mixing method patent issued to Tiansheng Pharmaceutical Group and the pharmaceutical composition patent held by the consortium comprising SICHUAN PHARMACEUTICAL.IN, SICHUAN XINGZHI ZHIHUI INTELLECTUAL PROPERTY OPERATION CO., LTD., together represent the dominant intellectual property portfolio for this drug combination. These patents not only define the manufacturing and clinical essence of cefoperazone/sulbactam but also have far-reaching implications in terms of market competition, future innovation, and generic drug production strategies. The multi-layered and jurisdiction-specific nature of these patents necessitates a thorough understanding by stakeholders—from clinicians to pharmaceutical executives—of how patent law intertwines with patient care and market sustainability.

Thus, from multiple angles—ranging from the technical details in the patents to the overarching legal and market implications—the answer to “Who holds the patent for Cefoperazone/Sulbactam?” is complex. It involves multiple entities: Tiansheng Pharmaceutical Group for specific process innovations and a collaborative group of companies including SICHUAN PHARMACEUTICAL.IN, among others, for the formulation aspects. The interplay of these patent rights supports continued innovation and market control, ultimately shaping the therapeutic landscape for this crucial antibiotic combination.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.